Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $60.55 USD
Change Today +0.01 / 0.02%
Volume 1.5M
As of 6:40 PM 02/9/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3 Giralda Farms

Madison, NJ 07940

United States

Phone: 973-520-2700


ng a real-time polymerase chain reaction assay, in addition to its immune fluorescent antibody assay. Cardiovascular and Metabolic Disease The company released a simplified CardioIQ interpretive report for its suite of CardioIQ advanced cardiovascular tests. The company incorporated an ASCVD (atherosclerotic cardiovascular disease) Risk Panel as part of the CardioIQ offering. This panel reports 10-year and lifetime atherosclerotic cardiovascular disease (ASCVD) risk on the CardioIQ report. The company developed and released a diabetes risk assessment panel. This panel provides a comprehensive assessment of diabetes risk that conforms to American Diabetes Association guidelines. The company developed and released a diabetes panel for non-alcoholic fatty liver disease that is supported by guidelines. Neurology The company launched a blood test panel to identify a severe, rapidly progressive but treatable form of autoimmune dementia and memory loss. The company launched a suite of new next-generation gene sequencing testing services to help diagnose the cause of various forms of epilepsy in adults and children. The company launched a new next-generation gene sequencing test service for initial assessment of Charcot-Marie Tooth disease. Women's Health The company introduced CFVantage, an evaluation of approximately 150 possible mutations for prenatal screening for cystic fibrosis. The company introduced access to the MaterniT21 Plus prenatal test developed by Sequenom for pregnant women at increased risk for fetal chromosomal abnormalities. The company introduced a cervical cancer screening report that includes prior PAP and HPV testing results. The company introduced the APTIMA mRNA assay using Surepath vial samples types to enhance its cervical cancer screening portfolio. Prescription Drug Monitoring and Toxicology The company launched testing for prescription drugs on oral fluid sample types. It expanded testing for anticonvulsants, including for eslicarbazepine. Diagnostic Solutions Clinical Trials Testing The company is a provider of central laboratory testing performed in connection with clinical research trials on new drugs, vaccines and certain medical devices. Clinical research trials are required by the FDA and non-U.S. regulatory authorities to assess the safety and efficacy of new drugs, vaccines and some medical devices. The company has clinical trials testing centers in the United States, the United Kingdom and India, and the company provides clinical trials testing in Argentina, Brazil, China and Singapore through affiliated laboratories. The company serves a range of large pharmaceutical, biotechnology and medical device companies. Risk Assessment Services ExamOne is a provider of risk assessment services to the life insurance industry in North America. The company also provides risk assessment services for insurance companies operating outside North America. The company’s risk assessment services comprise underwriting support services, including data gathering, paramedical examinations and clinical laboratory testing and analytics, designed to assist life insurance companies objectively to evaluate the mortality risks of applicants. Most specimen collections and paramedical examinations are performed by its network of paramedical examiners at the applicant's home or workplace, but they also are offered at approximately 600 company patient service centers in the United States and approximately 120 additional locations in North America. The company also contracts with third parties to coordinate providing these exams at approximately 350 additional locations outside North America. Diagnostic Products The company develops and manufactures products that enable healthcare professionals to make healthcare diagnoses. The company offers these products to a spectrum of customers in the United States and, through distributors, in other countries. Focus Diagnostics develops, manufactures and markets diagnostic products which could be performed on various instrument platforms. Focus Diagnostics' product lines include Simplexa molecular chemistries wi


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $60.55 USD +0.01

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $53.14 USD -0.06
BioMerieux €108.50 EUR +0.80
Hologic Inc $32.89 USD +0.14
Laboratory Corp of America Holdings $102.53 USD +1.59
Roper Technologies Inc $161.83 USD -0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation DGX Industry Range
Price/Earnings 12.4x
Price/Sales 1.2x
Price/Book 1.8x
Price/Cash Flow 11.0x
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact QUEST DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at